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With increasing numbers of children and adults undergoing
allogeneic haematopoietic stem cell transplantation (HSCT), neuro-
toxicity is emerging as an important cause of transplant-related
morbidity.1–3 The calcineurin inhibitor cyclosporine A (CI CSA) is the
most frequently used agent for prevention of GvHD in both adult
and paediatric patients. CSA is an established cause of post-
transplantation central nervous system (CNS) toxicity, typically
characterised by posterior reversible encephalopathy syndrome
(PRES).4 Even though neurological complications of CSA seldom
result in mortality, the necessitated withdrawal of this potent anti-
GvHD agent can have major implications on clinical outcome
particularly in the face of on-going GvHD. The spectrum of
CSA-related neurological complications has been well characterised
in several case series of paediatric HSCT recipients,5–7 however, long-
term follow-up data of those children who experience neurotoxicity
are lacking. Here, we present the outcome of 26 children who
developed CSA-neurotoxicity following allogeneic HSCT.
From a cohort of 569 consecutive paediatric allogeneic HSCT
recipients at our institution between 1 January 2003 and 31
December 2013, we retrospectively identiﬁed those children who
developed neurological complications at any time after the start
of conditioning whilst receiving CSA using a computerised search
of our patient database. Children with clinical symptoms of PRES
or neurological manifestations of thrombotic microangiopathy
(TMA)7 were included. Those with obvious alternate causes for
neurotoxicity were excluded. All children who suffered CNS
complications were clinically evaluated by a neurologist. Supple-
mentary investigations such as computed tomography (CT) or
magnetic resonance imaging (MRI) scan of head, cerebrospinal
ﬂuid analysis and electroencephalogram were used as appropriate
to identify the cause. PRES was diagnosed in accordance with its
well described MRI appearance.8 Hypodense lesions in the parieto-
occipital areas were considered to be CT ﬁndings consistent with
PRES. TMA was diagnosed based on clinical and laboratory
features of microangiopathic haemolytic anaemia and thrombo-
cytopenia. GvHD was diagnosed clinically and supported with
histological conﬁrmation where possible.9 IV CSA administration at
a dose of 5 mg/kg/day in two divided doses was commenced
either on day − 1 (2003–2008) or day − 3 (2009 onwards). Levels
were monitored twice weekly. Target trough serum levels
were 100–150 ng/mL for HLA-identical sibling transplants and
150–200 ng/mL for unrelated donor transplants.
During the 11-year study period, 569 paediatric allogeneic HSCTs
were performed at this centre. Twenty-six children developed
neurotoxicity associated with CSA (4.6%). Their demographics,
disease characteristics and transplant-related parameters are sum-
marised in Table 1. Median age at HSCT was 8.3 years (range
0.5–12.8 years). CSA+MMF was the most commonly employed
GvHD prophylaxis (n= 19), followed by CSA+MTX (n= 4) and CSA
alone (n= 3). In one patient (subject #19), CSA was changed to
Tacrolimus because of renal toxicity before the development of
neurotoxicity that is, in this patient neurotoxicity occurred while
being treated with Tacrolimus. Twenty-one children experienced CI-
related neurotoxicity during their primary transplant procedure and
5 children following their second HSCT, having tolerated CSA
without adverse events during their ﬁrst HSCT.
Median time from HSCT to neurotoxicity was 47.5 days (range day
–1 to +545) (Table 1). Clinical symptoms of neurotoxicity and
severity are listed in Table 1. Twenty-four out of 26 patients had
radiological evaluation of the brain with MRI, CT or both; 19 had
classical ﬁndings of PRES, 2 showed non-speciﬁc changes consistent
with encephalopathy and 3 had normal appearances of the brain.
CSA level in peripheral blood at the time of presentation with
neurotoxicity ranged from 64 to 256 ng/mL (Table 1).
Management of CI-induced neurotoxicity in addition to suppor-
tive care consisted of discontinuation of CSA/Tacrolimus in 25/26
patients. Neurological symptoms fully resolved in all patients except
in patient #9 who developed TMA and died shortly thereafter and
patient #3 who continues to require anticonvulsants despite
normalisation MRI appearance. One patient (#12) who presented
with seizures on day +24 and had non-speciﬁc features on MRI with
a normal EEG was continued on IV CSA along with anticonvulsants
and had no further neurological events.
After a median of 11 days post onset of CSA neurotoxicity
(range 0–597 days) a CI was reintroduced in 18 patients: in 10
patients CSA was used and in 12 patients Tacrolimus, 3 of whom
had failed re-challenge with CSA (Table 2). One patient received
Tacrolimus after having been successfully re-challenged with CSA
(patient #25). Eight of 18 patients re-challenged with a CI had
recurrent symptoms of neurotoxicity: 3 following re-challenge
with CSA, 2 following re-challenge with Tacrolimus and 3
following re-challenge with CSA as well as Tacrolimus sequentially.
In addition to attempted re-challenge with a CI, all but one patient
with grade I skin GvHD only before the onset of neurotoxicity,
received corticosteroids as GvHD prophylaxis/treatment. Other
immunosuppressive agents used are listed in Table 2.
Despite these measures, 7/9 patients (78%) who had no prior
GvHD, developed acute/late acute GvHD after onset of CSA
neurotoxicity whereas 13/17 had recurrence, persistence or progres-
sion of acute/late acute GvHD. Twenty-three patients were evaluable
for chronic GvHD as 2 died before day +100 and one patient had
second HSCT before day +100. Eighteen out of 23 (78%) had chronic
GvHD and this was extensive in 14 patients: 13 patients developed
chronic GvHD following CSA-neurotoxicity whereas pre-existing
chronic GvHD persisted or progressed in 5 patients (Table 2).
At a median of 176 days (range 7–1889 days) following
development of CSA-induced neurotoxicity 15/26 (58%) patients
died, most due to progressive GvHD or its complications (Table 2).
There were no acute deaths from neurotoxicity except in one
patient (subject #9) who had CSA-related TMA on day +61 and died
of encephalopathy and respiratory failure on day +68. Currently,
11/26 (42%) of children are alive a median of 8.2 years (range
5.5–13.1 years) after HSCT and a median of 7.8 years (range 5.5–12.1
years) after development of CSA-neurotoxicity. In contrast, during
the same study period in our institution, the overall survival at 5
years following allogeneic HSCT was 67.7% for haematological
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malignancy, 82.1% for immunodeﬁciency and 87.2% for metabolic
disorders. Of the 11 children who survived despite developing
CSA-related neurotoxicity, 4 (36%) have a signiﬁcantly impaired
quality-of-life due to sequelae of extensive chronic GvHD.
This case series of paediatric HSCT recipients who developed
CSA-related neurotoxicity illustrates that outcome following this
complication is notably poor: high non-relapse mortality of 58%
and signiﬁcant morbidity with 36% of survivors living with late
effects of extensive chronic GvHD. These ﬁndings are similar to
those in large case series of adult allogeneic HSCT recipients who
developed CSA-related neurotoxicity reporting 43–52% mortality
due to progressive GvHD/infection.10,11 In our study, outcome was
particularly poor in the 10 patients who had severe GvHD (Grade
III/IV) before the development of CSA-neurotoxicity: 8/10 died and
2 are alive with extensive vitiligo. In the same time period at our
institution, other patients with severe GvHD, but without the
added complication of CSA neurotoxicity had a far superior
survival rate of 70%.12 Hence it would seem that the development
of CSA neurotoxicity and consequent inability to tolerate CI,
adversely affected their prognosis. In future studies with larger
patient numbers, it would be useful to substantiate our ﬁndings
with multivariate analyses.
Development of CSA-related neurotoxicity poses a complex
clinical management situation as one of the most effective drugs
in the treatment and prevention of GvHD needs to be
discontinued promptly; sometimes in patients with on-going
GvHD. As symptoms of CSA-neurotoxicity usually resolve over
several days, re-challenge could be a viable option. Tacrolimus has
been used as alternative agent in the event of CSA-related
neurotoxicity but as it is also a CI, its use is similarly associated
with signiﬁcant neurotoxicity 7,13,14 as seen in 5 patients in our
case series. Nevertheless, re-challenge with a CI was tolerated in
56% of patients in this series, a similar proportion as that reported
by others.10 In those patients where re-challenge resulted in
recurrence of symptoms and use of CI was precluded perma-
nently, outcome appears particularly dismal with overall survival
of 13% (1/8) in this case series.
Evidence for the optimal approach of prophylaxis/management of
GvHD when use of CI is contra-indicated is not available. In this case
series, all but one patient received corticosteroids. In addition, as the
combination of CSA and MMF is the most common GvHD
prophylaxis regimen in our centre, the majority of patients were
already receiving MMF at the time of development of CSA
neurotoxicity. The efﬁcacy of MMF as sole anti-GvHD agent is
limited,13 and on its own it does not provide satisfactory GvHD
prophylaxis or treatment. Sirolimus, which has a completely different
mechanism of action to the CI provides another option. Although
Sirolimus can also cause neurotoxicity, this has mostly been reported
when it has been used in combination with CSA.15 In this series,
Sirolimus was only used in ﬁve patients but this agent may
potentially be increasingly used in this clinical situation in future.
In conclusion, this case series illustrates the dismal prognosis in
patients following the development of CI-related neurotoxicity and
the complexities of managing GvHD in this situation. There is a need
for further studies to determine the optimal treatment approach to
improve outcome following this rare but serious complication.
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